DeepEvidence: Empowering Biomedical Discovery with Deep Knowledge Graph Research
Zifeng Wang, Zheng Chen, Ziwei Yang, Xuan Wang, Qiao Jin, Yifan Peng, Zhiyong Lu, Jimeng Sun · 2026
Read DeepEvidence: Empowering Biomedical Discovery with Deep Knowledge Graph Research by Zifeng Wang, Zheng Chen, Ziwei Yang, Xuan Wang, Qiao Jin, Yifan Peng, Zhiyong Lu, Jimeng Sun (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2601-11560.txt.
Introduction
Zifeng Wang and seven coauthors launch DeepEvidence for biomedical discovery. Their 2026 preprint builds on biomedical knowledge graphs. Such graphs encode vast, mixed data for the life sciences. Literature, genes, pathways, drugs, diseases, and trials all sit inside.
Using those graphs jointly for discovery stays hard today. Their structures differ from one resource to the next. They evolve over time as new studies land. Cross-resource alignment is limited and needs manual work. That hand work caps the depth and scale of exploration. DeepEvidence aims at deep graph research with less friction. Better tooling could speed drug and disease insight.
Catalog record
| CREATOR | Zifeng Wang, Zheng Chen, Ziwei Yang, Xuan Wang, Qiao Jin, Yifan Peng, Zhiyong Lu, Jimeng Sun |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 93 KB |
| VERSION | 1.0 |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2601-11560
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
DeepEvidence: Empowering Biomedical Discovery with Deep Knowledge Graph Research Zifeng Wang, Zheng Chen, Ziwei Yang, Xuan Wang, Qiao Jin, Yifan Peng, Zhiyong Lu, Jimeng Sun Abstract Biomedical knowledge graphs (KGs) encode vast, heterogeneous information spanning literature, genes, pathways, drugs, diseases, and clinical trials, but leveraging them collectively for scientific discovery remains difficult. Their structural differences, continual evolution, and limited cross-resource alignment require substantial manual integration, limiting the depth and scale of knowledge exploration. We introduce DeepEvidence, an AI-agent framework designed to perform Deep Research across various heterogeneous biomedical KGs. Unlike generic Deep Research systems that rely primarily on internet-scale text, DeepEvidence incorporates specialized knowledge-graph tooling and coordinated exploration strategies to systematically bridge heterogeneous resources. At its core is an orchestrator that directs two complementary agents: Breadth-First ReSearch (BFRS) for broad, multi-graph entity search, and Depth-First ReSearch (DFRS) for multi-hop, evidence-focused reasoning. An internal, incrementally built evidence graph provides a structured record of retrieved entities, relations, and supporting evidence. To operate at scale, DeepEvidence includes unified interfaces for querying diverse biomedical APIs and an execution sandbox that enables programmatic data retrieval, extraction, and analysis. Across established deep-reasoning benchmarks and four key stages of the biomedical discovery lifecycle: drug discovery, pre-clinical experimentation, clinical trial development, and evidence-based medicine, DeepEvidence demonstrates substantial gains in systematic exploration and evidence synthesis. These results highlight the potential of knowledge-graph-driven Deep Research to accelerate biomedical discovery. Introduction Knowledge graphs have now become foundational to contemporary biomedical discovery, supporting tasks across literature mining, chemical and drug annotation, gene and protein characterization, pathway analysis, and disease-phenotype understanding. Prominent examples include PubTator [ 37 ] and PKG [ 39 ] for publication-derived knowledge, KEGG [ 16 ] and Gene Ontology [ 4 ] for pathways and functional annotation, OpenTargets [ 3 ] for gene–disease associations, and BioThings [ 19 ] for unified chemical and gene annotations. Together, these knowledge bases provide rich, complementary representations of biomedical entities, relations, and annotations that underpin modern research workflows. Yet, leveraging them collectively remains highly challenging: they differ markedly in structure, evolve continuously, and rarely align seamlessly, resulting in limited interoperability and cross-resource reasoning difficult in practice. As a result, substantial manual effort is still required to integrate, align, or traverse these heterogeneous knowledge graphs, and existing standardization or merging initiatives remain labor-intensive and difficult to sustain at scale. Incorporating artificial intelligence (AI) agents into biomedical research has become an area of rapidly growing interest, with applications emerging across systematic literature review [ 34 , 33 ] , genomics research [ 35 , 32 ] , spatial biology [ 30 ] , biomarker discovery [ 28 ] , and beyond. Central to this trend is the concept of the AI scientist: LLM-driven agents that interact with diverse scientific knowledge sources and computational tools to streamline, enhance, or automate components of the research process [ 9 , 13 , 2 ] . Alongside these efforts, several general-purpose biomedical agents have also been developed [ 15 , 10 ] . Within this landscape, “Deep Research” represents a class of LLM-based agents capable of end-to-end scientific inquiry by autonomously searching, reasoning, and synthesizing evidence from literature and knowledge bases, as exemplified by OpenAI DeepResearch [ 22 ] , Gemini Deep Research [ 12 ] , Perplexity Deep Research [ 23 ] , and so on. Despite these advances, substantial challenges remain. In particular, most existing agents rely solely on internet-scale text corpora, leaving open a central question: Can we design agents that deeply and systematically explore large, heterogeneous biomedical knowledge graphs, bridging them to uncover the subtle relationships and connections essential for modern biomedical discovery? Here, we present DeepEvidence, an AI agent system specifically designed to enable deep research with biomedical knowledge graphs. Unlike generic Deep Research systems, DeepEvidence leverages specialized knowledge-graph tooling to locate and link entities across heterogeneous graphs, and to navigate them through a coordinated combination of Breadth-First ReSearch (BFRS) and Depth-First ReSearch (DFRS): two complementary strategies for systematic graph exploration. DeepEvidence further incorporates an internal evidence-graph memory that is continuously updated as the agent traverses and synthesizes information, providing a structured and transparent record of the discovery process. We instantiate these principles in an orchestrator–sub-agent architecture comprising dedicated BFRS and DFRS agents that collaborate to build and refine the final evidence graph (Figure 1 ). Our empirical evaluation begins by assessing DeepEvidence ’s performance across established biomedical benchmarks that require deep exploration and reasoning over literature, including Humanity’s Last Exam (HLE) [ 24 ] , LabBench-LitQA2 [ 18 ] , SuperGPQA [ 5 ] , and TrialPanorama-EvidenceQA [ 36 ] . We then demonstrate DeepEvidence ’s practical utility across four critical stages of the biomedical discovery lifecycle: (1) drug discovery, (2) pre-clinical in vivo experimentation, (3) clinical trial development, and (4) evidence-based medicine. Together, these results illustrate the potential of knowledge-graph-driven Deep Research to support and accelerate biomedical discovery. Results Overview of DeepEvidence DeepEvidence is a Deep Research framework designed to operate over heterogeneous biomedical knowledge graphs (KGs) with LLM-driven AI agents. At its core is an orchestrator agent that delegates tasks to a set of specialized sub-agents, termed research agents, which execute knowledge-graph exploration (Figure 1a ). Throughout the process, the orchestrator maintains and incrementally updates an internal evidence graph that records the key entities and relations critical to answer the query (Figure 1b ). The research agents operate in two complementary modes. Breadth-First ReSearch (BFRS) issues broad, multi-graph queries to rapidly survey first-hop neighborhoods (e.g., identifying drugs linked to a disease across disease–drug or gene–disease graphs) and capture a wide set of candidate entities and relations. Depth-First ReSearch (DFRS) builds on the important entities surfaced by BFRS and performs deeper, multi-hop exploration when the question requires multi-step reasoning or richer evidence discovery (e.g., recursively tracing references across publications to construct a comprehensive evidence graph for systematic literature review). We refer to these two modes as BFRS and DFRS, rather than the conventional BFS/DFS, because the proposed AI agents choose traversal steps autonomously rather than follow fixed graph-theoretic rules. Also, AI agents can bridge across heterogeneous knowledge graphs by recognizing shared entities or inferring cross-graph relations (referred to as “Bridge entities” in Figure 1a ). We created an integrated environment and toolset that allow DeepEvidence to explore diverse biomedical KGs at scale (Figure 1 c ). Many biomedical KGs are accessible through heterogeneous web APIs, so to support efficient BFRS, we implemented unified entity-search and data-fetching interfaces across major biomedical domains, including publications, clinical trials, chemicals, genes, drugs, diseases, phenotypes, and proteins. For example, a single drug query issued by an agent can automatically trigger parallel lookups across KEGG [ 16 ] , ChEMBL [ 40 ] , OpenFDA [ 8 ] , OpenTargets [ 3 ] , and other resources. Because these operations involve large numbers of API calls and produce heterogeneous data, we equipped the system with an execution sandbox that enables agents to conduct research programmatically. Within this sandbox, agents can write and execute code to query knowledge-graph APIs at scale, persist retrieved results as structured files (e.g., spreadsheets), and perform downstream extraction and analysis all within a controlled environment. This design ensures that multi-step research workflows remain both efficient and reproducible. DeepEvidence is designed to support general biomedical